New Delhi: J Mitra & Company, one of the leading players in the IVD space, has launched India’s first Covid-19 Neutralizing Antibody Microlisa Elisa Test with all necessary approvals, including from the Drug Controller General of India (DCGI). The test has also undergone a successful product validation.
Virus neutralization remains the gold standard for determining antibody efficacy. Covid-19 Neutralizing Antibody Microlisa Elisa Test is the first commercial laboratory test to detect neutralizing antibodies against SARS-CoV-2, the virus that causes Covid-19. The test kit will help highlight the efficacy of the vaccines on the human body and the development of the antibodies to fight the virus and help identify potential plasma donors. The test kit has high sensitivity (> 95%) and Specificity (100%).
Expected benefits:
-
Assist in the tracking of infection chains
-
Answer epidemiological, virological, and clinic questions, including, but not limited to, whether a robust antibody response has occurred.
-
Answer how many infected individuals have remained asymptomatic
-
The presence of neutralizing antibodies highlights protective immunity against viral infections
-
Identify individuals with high levels of neutralizing antibodies as potential candidates for plasma donation to severely infected COVID patients.